Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Midkine (MDK) as a central regulator of the tumor microenvironment: From developmental cytokine to therapeutic target.

Cancer letters·2026
Same author

Midkine as a therapeutic node in NF1-driven neuro‑oncology: Biology, biomarkers, and translational strategies.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation.

Neuro-oncology advances·2026
Same author

EC359 Enhances Trametinib Efficacy in <i>Ras</i>/<i>Raf</i>-Driven Ovarian Cancer by Suppressing LIFR Signaling.

Biomolecules·2025
Same author

Significance of Midkine Signaling in Women's Cancers: Novel Biomarker and Therapeutic Target.

International journal of molecular sciences·2025
Same author

The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer.

Molecular cancer therapeutics·2025

Related Experiment Video

Updated: Jun 22, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Elevated aromatase expression correlates with cervical carcinoma progression.

Poornachand Veerapaneni1, Nameer Kirma, Hareesh B Nair

  • 1Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

Gynecologic Oncology
|June 27, 2009
PubMed
Summary

Aromatase protein and activity are elevated in cervical cancers, correlating with disease stage. Inflammatory cytokines like IL-6 and TNFalpha also correlate with aromatase expression, suggesting a role in cervical carcinogenesis.

Related Experiment Videos

Last Updated: Jun 22, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Aromatase mRNA is upregulated in cervical carcinomas, indicating potential local estrogen production contributing to cancer.
  • Previous research suggests a link between aromatase expression and cervical carcinogenesis.

Purpose of the Study:

  • To investigate aromatase protein and activity levels in cervical carcinomas.
  • To determine the correlation between aromatase expression and cervical cancer disease stage.
  • To examine the relationship between inflammatory cytokines (IL-6, TNFalpha) and aromatase expression.

Main Methods:

  • Real-time RT-PCR, Western blot, and immunohistochemistry were used to assess aromatase expression in tissue.
  • Aromatase activity was measured using the tritiated water release method.
  • Expression levels of IL-6 and TNFalpha were also analyzed.

Main Results:

  • Cervical carcinomas showed increased aromatase protein and activity compared to normal tissue.
  • Aromatase RNA levels significantly correlated with disease progression, peaking in stage IV tumors.
  • Elevated expression of aromatase promoters 1.3 and 1.4 was observed in tumors and cancer cells.
  • Significant correlations were found between aromatase expression and inflammatory cytokines IL-6 and TNFalpha (R(2)>0.9).
  • TNFalpha treatment induced aromatase expression in cervical cancer cells.

Conclusions:

  • Increased aromatase protein, activity, and its correlation with disease stage implicate aromatase in cervical carcinogenesis.
  • The strong correlation with IL-6 and TNFalpha suggests these cytokines may induce aromatase expression.
  • Experimental evidence confirms TNFalpha can induce aromatase expression in cervical cancer cells.